In this issue:
Lymphoma selection
CISL: P-MZL prognostic factors and optimal management
Targeting B-cell lymphomas with CD22 glycan ligands
LTR derepression in lymphoma pathogenesis
Chemotherapy without radiotherapy in ES Hodgkin’s lymphoma
Leukaemia selection
Lenalidomide and CD154 expression in CLL cells
ALFA-9802: GM-CSF priming in AML
Rituximab + fludarabine/cyclophosphamide in CLL
Dasatinib vs. imatinib in chronic-phase CML
Nilotinib vs. imatinib in CML
Ofatumumab in fludarabine-refractory CML
Please login below to download this issue (PDF)